Recent

% | $
Quotes you view appear here for quick access.

Array BioPharma Inc. Message Board

  • too_much_sunshine too_much_sunshine Jul 29, 2013 4:04 PM Flag

    New Celgene Licencing Deal

    I was wondering what that price action was about.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • mdplanet@ymail.com mdplanet Jul 29, 2013 4:18 PM Flag

      Too funny. At 3:59 I was getting upset it was closing at the low of the day. Then I glanced at the time & sales window at 4:00 and thought I was looking at the wrong stock. LOL

      Look at the potential with this company:

      About Array BioPharma Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company and currently expects significant progress toward generating data to support our upcoming Phase 3 / pivotal trial decisions. Novartis began a Phase 3 trial evaluating Array-invented MEK162 in NRAS-mutant melanoma in July 2013 and expects to begin a Phase 3 trial in BRAF-mutant melanoma in 2013. In addition, Array began a Phase 3 trial evaluating MEK162 in low-grade serous ovarian cancer under the license agreement with Novartis in June 2013 . AstraZeneca began a pivotal trial with Array-invented selumetinib in thyroid cancer in May 2013 and expects to begin a Phase 3 trial in non-small cell lung cancer in 2013. Three other Array-invented drugs are also approaching Phase 3 or pivotal trial decisions which are expected by the end of 2013. These include Array's wholly-owned drugs, ARRY-520 and ARRY-614, and one partnered program, danoprevir (with InterMune/Roche).

      Do you know any other company with this much happening? It is a machine, sunshine.

      • 1 Reply to mdplanet
      • Indeed, mdplanet. And I know your question was rhetorical, but I'll answer it anyway. For less than a multi-billion market cap there is no other drug developer with this much happening. The cash flow generated by the new deals and milestones is becoming significant. If I remember correctly, Ron Squarer stated back in the 4th Quarter that Array was approaching a time where they could be sustainable on the payments from partners. He hasn't used that language again, and obviously they've done some financing and debt restructuring since, so I'm sure that he doesn't want to be tied to such a notion. However, it is not unreasonable to see them as now substantially funded by all these deals. Presumably that will only get better with time.

        The result is what appears to be a combination of low risk and huge long-term upside, and that's very rare in biotech or any other investing space.

    • Array is a machine. It just keeps generating drug candidates and deals.

      • 2 Replies to too_much_sunshine
      • I am so surprised that Array isn't more well known. I was doing research last spring and discovered the depth of their pipeline as opposed to their market cap & I was blown away. I was also lucky to have added another 30% this morning @ 6.33. I'm liking what I see and I think it's just a matter of time before the market recognizes Array's potential.......glta

      • Array BioPharma Inc. (ARRY) announced a strategic collaboration with Celgene Corporation for an Array-invented preclinical development program targeting a novel inflammation pathway. Under the terms of the agreement Array will receive an up-front payment of $11 million and Celgene will have an exclusive option to license multiple clinical development candidates. Array is entitled to receive potential milestone payments of up to $376 million based upon achieving certain development, regulatory and sales objectives. Array is also entitled to receive royalties on net sales of all drugs and will retain all rights to the program if Celgene does not exercise its option.

        Stock up 10% AH

 
ARRY
2.55+0.05(+2.00%)Feb 11 4:00 PMEST